Royal Bank of Canada Raises Amedisys (NASDAQ:AMED) Price Target to $100.00

Amedisys (NASDAQ:AMED) had its target price increased by Royal Bank of Canada from $97.00 to $100.00 in a report issued on Monday, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the health services provider’s stock.

Separately, StockNews.com started coverage on Amedisys in a research note on Saturday, March 23rd. They set a buy rating for the company. Seven analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Amedisys presently has an average rating of Hold and an average price target of $97.50.

Amedisys Stock Performance

Shares of NASDAQ AMED opened at $92.16 on Monday. The firm has a market cap of $3.01 billion, a P/E ratio of -297.28, a PEG ratio of 4.34 and a beta of 0.86. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.05 and a current ratio of 1.05. The stock has a fifty day moving average price of $93.56 and a two-hundred day moving average price of $93.59. Amedisys has a 1 year low of $71.19 and a 1 year high of $96.44.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, February 21st. The health services provider reported $0.94 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.10). The company had revenue of $570.79 million for the quarter, compared to the consensus estimate of $566.85 million. Amedisys had a positive return on equity of 12.76% and a negative net margin of 0.44%. The business’s revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.16 earnings per share. Research analysts forecast that Amedisys will post 4.54 EPS for the current fiscal year.

Institutional Trading of Amedisys

Hedge funds have recently modified their holdings of the business. Pinebridge Investments L.P. purchased a new stake in shares of Amedisys in the second quarter valued at $26,000. KBC Group NV purchased a new stake in shares of Amedisys in the fourth quarter valued at $41,000. Neo Ivy Capital Management purchased a new stake in shares of Amedisys in the second quarter valued at $44,000. Covestor Ltd lifted its holdings in shares of Amedisys by 88.9% in the first quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock valued at $56,000 after purchasing an additional 152 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in shares of Amedisys in the first quarter valued at $67,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.